IL228633B - Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) - Google Patents

Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Info

Publication number
IL228633B
IL228633B IL228633A IL22863313A IL228633B IL 228633 B IL228633 B IL 228633B IL 228633 A IL228633 A IL 228633A IL 22863313 A IL22863313 A IL 22863313A IL 228633 B IL228633 B IL 228633B
Authority
IL
Israel
Prior art keywords
tfpi
monoclonal antibodies
antibodies against
tissue factor
pathway inhibitor
Prior art date
Application number
IL228633A
Other languages
English (en)
Hebrew (he)
Other versions
IL228633A0 (en
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL228633(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IL228633A0 publication Critical patent/IL228633A0/en
Publication of IL228633B publication Critical patent/IL228633B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL228633A 2011-04-01 2013-09-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) IL228633B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
PCT/US2012/031538 WO2012135671A2 (en) 2011-04-01 2012-03-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number Publication Date
IL228633A0 IL228633A0 (en) 2013-12-31
IL228633B true IL228633B (en) 2018-03-29

Family

ID=46932389

Family Applications (4)

Application Number Title Priority Date Filing Date
IL228633A IL228633B (en) 2011-04-01 2013-09-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL257145A IL257145A (en) 2011-04-01 2018-01-25 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL274686A IL274686B (en) 2011-04-01 2020-05-14 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL283829A IL283829A (en) 2011-04-01 2021-06-09 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL257145A IL257145A (en) 2011-04-01 2018-01-25 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL274686A IL274686B (en) 2011-04-01 2020-05-14 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL283829A IL283829A (en) 2011-04-01 2021-06-09 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (Direct)
EP (1) EP2694544B1 (Direct)
JP (4) JP6170903B2 (Direct)
KR (2) KR101995302B1 (Direct)
CN (2) CN103797030B (Direct)
AU (3) AU2012236296A1 (Direct)
BR (1) BR112013025376A2 (Direct)
CA (2) CA2831907C (Direct)
CL (1) CL2013002811A1 (Direct)
CO (1) CO6890074A2 (Direct)
CR (1) CR20130499A (Direct)
CU (1) CU20130128A7 (Direct)
CY (1) CY1121538T1 (Direct)
DK (1) DK2694544T3 (Direct)
DO (1) DOP2013000218A (Direct)
EA (2) EA034214B1 (Direct)
EC (1) ECSP13012913A (Direct)
ES (1) ES2722824T3 (Direct)
GT (1) GT201300229A (Direct)
HK (1) HK1243426A1 (Direct)
HR (1) HRP20190467T1 (Direct)
HU (1) HUE042706T2 (Direct)
IL (4) IL228633B (Direct)
LT (1) LT2694544T (Direct)
MX (1) MX2013011218A (Direct)
MY (2) MY190951A (Direct)
PE (1) PE20141149A1 (Direct)
PH (4) PH12013502039B1 (Direct)
PL (1) PL2694544T3 (Direct)
PT (1) PT2694544T (Direct)
RS (1) RS58633B1 (Direct)
SG (2) SG193594A1 (Direct)
SI (1) SI2694544T1 (Direct)
TR (1) TR201905101T4 (Direct)
UA (1) UA113623C2 (Direct)
WO (1) WO2012135671A2 (Direct)
ZA (1) ZA201308169B (Direct)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
BRPI0924058B1 (pt) † 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
CA2793465C (en) 2010-03-19 2022-06-14 Baxter International Inc. Tfpi inhibitors and methods of use
MY190951A (en) * 2011-04-01 2022-05-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2013141965A1 (en) * 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
CA2868789A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105209497B (zh) * 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
ES2657304T3 (es) 2013-03-15 2018-03-02 Bayer Healthcare Llc Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética
WO2015007880A1 (en) * 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US11279771B2 (en) * 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
AU2015384281B2 (en) * 2015-02-25 2018-11-22 Mogam Institute For Biomedical Research Novel antibody binding to TFPI and composition comprising the same
KR20230074843A (ko) 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BRPI0924058B1 (pt) * 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
ES2765418T3 (es) * 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
MY190951A (en) * 2011-04-01 2022-05-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
US20180194857A1 (en) 2018-07-12
PH12019500441A1 (en) 2020-10-12
EP2694544A2 (en) 2014-02-12
PH12019500439A1 (en) 2020-10-12
JP2017113019A (ja) 2017-06-29
RS58633B1 (sr) 2019-05-31
AU2012236296A1 (en) 2013-10-24
TR201905101T4 (tr) 2019-05-21
DK2694544T3 (en) 2019-04-15
IL283829A (en) 2021-07-29
EA034214B1 (ru) 2020-01-17
GT201300229A (es) 2014-11-13
CN103797030B (zh) 2017-05-31
HRP20190467T1 (hr) 2019-05-03
CO6890074A2 (es) 2014-03-10
JP6363747B2 (ja) 2018-07-25
CN103797030A (zh) 2014-05-14
PH12013502039A1 (en) 2013-12-16
CA2831907C (en) 2020-03-24
KR20140019428A (ko) 2014-02-14
US20170107298A1 (en) 2017-04-20
WO2012135671A2 (en) 2012-10-04
HUE042706T2 (hu) 2019-07-29
KR101995302B1 (ko) 2019-07-02
ECSP13012913A (es) 2014-02-28
SI2694544T1 (sl) 2019-06-28
CY1121538T1 (el) 2020-05-29
LT2694544T (lt) 2019-04-25
ZA201308169B (en) 2016-03-30
US20190194353A1 (en) 2019-06-27
US20140294832A1 (en) 2014-10-02
PT2694544T (pt) 2019-04-02
DOP2013000218A (es) 2013-11-15
WO2012135671A3 (en) 2012-12-13
CN107090046A (zh) 2017-08-25
EA201991704A2 (ru) 2020-03-31
NZ615969A (en) 2016-01-29
EP2694544A4 (en) 2015-03-25
US20220041752A1 (en) 2022-02-10
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
JP2014511685A (ja) 2014-05-19
BR112013025376A2 (pt) 2017-07-25
IL228633A0 (en) 2013-12-31
UA113623C2 (uk) 2017-02-27
CA3068997A1 (en) 2012-10-04
CU20130128A7 (es) 2014-03-26
JP2021019619A (ja) 2021-02-18
JP6170903B2 (ja) 2017-07-26
MX2013011218A (es) 2013-10-17
ES2722824T3 (es) 2019-08-19
AU2019201814A1 (en) 2019-04-04
IL274686A (en) 2020-06-30
CR20130499A (es) 2013-10-24
PL2694544T3 (pl) 2019-07-31
HK1243426A1 (zh) 2018-07-13
EP2694544B1 (en) 2019-01-23
CA2831907A1 (en) 2012-10-04
KR20190079698A (ko) 2019-07-05
IL257145A (en) 2018-03-29
SG193594A1 (en) 2013-10-30
PE20141149A1 (es) 2014-08-28
PH12013502039B1 (en) 2013-12-16
JP2018172411A (ja) 2018-11-08
AU2017203105A1 (en) 2017-06-01
CL2013002811A1 (es) 2014-02-28
EA201301107A1 (ru) 2014-11-28
IL274686B (en) 2021-09-30
SG10201602606UA (en) 2016-04-28
MY165499A (en) 2018-03-27
EA201991704A3 (ru) 2020-06-30

Similar Documents

Publication Publication Date Title
IL283829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL277391A (en) Monoclonal antibodies are effective against tissue factor pathway inhibitor (TFPI)
IL250640A0 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
ZA201400768B (en) Interleukin-31 monoclonal antibody
IL220404A (en) Antiseptic antibodies
SMT201600193B (it) Nuovo anticorpo anti-dr5
ZA201206835B (en) New humanized anti-cd20 monoclonal antibory
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed